Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
by
Geng, Chenchen
, Wang, Zhe
, Li, Jinyang
, Gao, Songyan
, Yuan, Xing
, Li, Yinghua
, Chen, Si
, Li, Xiang
, Ma, Bohan
, Lu, Wuyuan
, Hu, Hong-Gang
in
Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Cancer
/ Cell culture
/ Cell cycle
/ Cell Cycle Proteins - metabolism
/ Clinical trials
/ Colorectal cancer
/ Design
/ Experiments
/ Humans
/ Hydrocarbons
/ Laboratory animals
/ Neoplasms - drug therapy
/ Peptides
/ Peptides - chemistry
/ Proteins
/ Proto-Oncogene Proteins c-mdm2 - metabolism
/ Tumor Suppressor Protein p53 - metabolism
/ Tumors
2022
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
by
Geng, Chenchen
, Wang, Zhe
, Li, Jinyang
, Gao, Songyan
, Yuan, Xing
, Li, Yinghua
, Chen, Si
, Li, Xiang
, Ma, Bohan
, Lu, Wuyuan
, Hu, Hong-Gang
in
Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Cancer
/ Cell culture
/ Cell cycle
/ Cell Cycle Proteins - metabolism
/ Clinical trials
/ Colorectal cancer
/ Design
/ Experiments
/ Humans
/ Hydrocarbons
/ Laboratory animals
/ Neoplasms - drug therapy
/ Peptides
/ Peptides - chemistry
/ Proteins
/ Proto-Oncogene Proteins c-mdm2 - metabolism
/ Tumor Suppressor Protein p53 - metabolism
/ Tumors
2022
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
by
Geng, Chenchen
, Wang, Zhe
, Li, Jinyang
, Gao, Songyan
, Yuan, Xing
, Li, Yinghua
, Chen, Si
, Li, Xiang
, Ma, Bohan
, Lu, Wuyuan
, Hu, Hong-Gang
in
Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Cancer
/ Cell culture
/ Cell cycle
/ Cell Cycle Proteins - metabolism
/ Clinical trials
/ Colorectal cancer
/ Design
/ Experiments
/ Humans
/ Hydrocarbons
/ Laboratory animals
/ Neoplasms - drug therapy
/ Peptides
/ Peptides - chemistry
/ Proteins
/ Proto-Oncogene Proteins c-mdm2 - metabolism
/ Tumor Suppressor Protein p53 - metabolism
/ Tumors
2022
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
Journal Article
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
2022
Request Book From Autostore
and Choose the Collection Method
Overview
Although stapled peptides offer a powerful solution to overcome the susceptibility of linear peptides to proteolytic degradation and improve their ability to cross membranes, an efficient and durable disease treatment strategy has not yet been developed due to the inevitable elimination of peptide inhibitors and rapid accumulation of target proteins.
Herein we developed stapled peptide-based proteolysis-targeting chimeras (SP-PROTACs), that simultaneously exhibited improved cellular uptake and proteolytic stability attributed to the stapled peptides, and efficient target protein degradation promoted by the PROTACs. Based on the PMI peptide with dual specificity for both MDM2 and MDMX, a series of SP-PROTACs were designed.
Among them, the optimized SPMI-HIF2-1 exhibited similar binding affinity with MDM2 and MDMX but obviously higher helical contents, improved proteolytic stability, better cellular permeability, and a better pharmacokinetic profile compared with its linear counterpart. Importantly, SPMI-HIF2-1 could effectively kill cancer cells and inhibit tumor progression in subcutaneous and orthotopic colorectal cancer xenograft models through simultaneously promoting the atypical degradation of both MDM2 and MDMX and durable p53 activation. An FP-based binding assay and structural modeling analysis of the ternary complex suggested that SPMI-HIF2-1 simultaneously bound with the target protein and E3 ligase.
Our findings not only provide a new class of anticancer drug candidates, but also bridge the gap and reduce the physical distance between peptides and PROTACs.
Publisher
Ivyspring International Publisher Pty Ltd
This website uses cookies to ensure you get the best experience on our website.